A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer
Condition: HER2-positive Early Breast Cancer Interventions: Drug: SIBP-01; Drug: Herceptin; Drug: Docetaxel; Drug: Carboplatin Sponsors: Shanghai Institute Of Biological Products; Fudan University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Docetaxel | HER2 | Herceptin | Research | Study | Taxotere